Every Form 4 that Skye Bioscience (SKYE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SKYE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SKYE filings page.
Skye Bioscience, Inc. (SKYE) reported insider-related sales of common stock by funds associated with director and ten percent owner Andrew J. Schwab. Over August 18–20, 2026, entities including 5AM Ventures II, L.P., 5AM Co-Investors II, L.P., and 5AM Ventures VII, L.P. sold shares at weighted-average prices ranging from $0.33 to $0.41 per share. All holdings are reported as indirect; Schwab is a managing member of the general partners of these funds and disclaims beneficial ownership except to the extent of his pecuniary interest.
Skye Bioscience, Inc. (SKYE) reported that affiliated 5AM investment funds sold shares of its Common Stock. Over August 18–20, 2026, 5AM Ventures II, L.P., 5AM Co-Investors II, L.P. and 5AM Ventures VII, L.P. sold a combined 375,840 shares in open-market or private transactions at weighted-average prices within $0.33–$0.41 per share.
The shares are held by the 5AM funds, whose general partners and managing members, including John Diekman, Kush Parmar, Andrew J. Schwab and Scott M. Rocklage, may be deemed to share voting and investment power but disclaim beneficial ownership beyond their pecuniary interests.
DHILLON PUNIT reported acquisition or exercise transactions in this Form 4 filing.
Skye Bioscience CEO Punit Dhillon received a grant of 1,090,000 restricted stock units tied to common stock on August 7, 2026. Each RSU represents one share and will vest on August 31, 2027, subject to continued employment or certain termination conditions under his Executive Employment Agreement. Following this award, he reports 1,419,823 shares held directly plus 9,343 shares held indirectly through a trust.
Skye Bioscience director Karen L. Smith received a grant of stock options covering 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. They vest in equal monthly installments over the one-year period beginning March 31, 2026. Following this grant, she holds 75,000 stock options directly.
Skye Bioscience Chief Scientific Officer Christopher Twitty reported compensation-related stock option changes with no open-market trading of common shares. On March 31, 2026, he received several new stock option grants, including 200,000 options, 150,000 options, and 75,000 options to buy common stock at exercise prices of $0.615 or $0.610 per share.
The filing also shows matching dispositions back to the company of older options with higher exercise prices ranging from $2.89 to $14.56, effectively repricing these awards. Footnotes explain that the board approved a one-time repricing to $0.615 per share for certain options and clarify multi-year monthly vesting schedules and a prior administrative vesting disclosure error.
Skye Bioscience director Annalisa Jenkins received a new stock option grant covering 75,000 shares of Common Stock. The option has an exercise price of $0.615 per share and expires on March 31, 2036. It vests in equal monthly installments over one year beginning March 31, 2026.
Skye Bioscience director Deborah H. Charych received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $0.6150 per share, expires on March 31, 2036, and was awarded at no cost as a compensation grant.
The stock option vests in equal monthly installments over a one-year period beginning March 31, 2026. Following this grant, Charych holds 75,000 stock options directly, giving her the right to buy an equivalent number of common shares if she chooses to exercise in the future.
Skye Bioscience director Paul A. Grayson received a grant of stock options for 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. The award vests in equal monthly installments over one year beginning March 31, 2026, and represents his full reported option holdings from this filing.
Skye Bioscience director Andrew J. Schwab received a grant of stock options covering 75,000 shares of common stock at an exercise price of $0.615 per share. The options were awarded at no upfront cost, expire on March 31, 2036, and vest in equal monthly installments over one year beginning March 31, 2026. This filing reflects a compensation-related equity award rather than an open-market purchase or sale of shares.
Skye Bioscience Chief Operating Officer Diep Tuan Tu reported a board-approved, one-time repricing of several stock option awards effective March 31, 2026. Existing options with exercise prices between $2.89 and $14.56 per share were surrendered and replaced with new options for the same share amounts at a $0.615 exercise price, matching the closing price on the repricing date.
The grants include, among others, a 150,000-share option expiring on February 25, 2035 and additional options for 75,000, 22,021, 9,194, 8,000 and 7,080 shares at the same $0.615 exercise price. These options generally vest in equal monthly installments over four years from their original vesting start dates and become fully vested upon a change in control. The filing reflects compensation-related option adjustments, not open-market purchases or sales of common stock.
Skye Bioscience reported that Chief Executive Officer Punit Dhillon had several existing stock option grants repriced effective March 31, 2026. Options covering blocks such as 650,000 and 250,000 shares were canceled and replaced with new options for the same share amounts, now carrying a $0.615 per-share exercise price, which matches the closing stock price on the repricing date. According to the disclosure, all other terms of each stock option remain unchanged.
One grant is already fully vested, while others continue to vest in equal monthly installments over four-year periods tied to original grant dates in 2023 and 2024. Each of these options becomes fully vested if there is a change in control of the company. These are compensation-related derivative transactions only and do not involve any open-market purchases or sales of common shares.
Skye Bioscience director receives stock option grant. Director Andrew J. Schwab was granted a stock option for 35,000 shares of Skye Bioscience, Inc. common stock on February 6, 2026. The option has an exercise price of $0.82 per share and was awarded at no cost to him.
The option vests in equal monthly installments over a one-year period beginning January 19, 2026, and is exercisable until February 6, 2036. Following this grant, Schwab holds 35,000 derivative securities directly in the form of this stock option.
Skye Bioscience director Grayson Paul A. received a grant of stock options on February 6, 2026. The award covers 35,000 stock options to buy Skye Bioscience common stock at an exercise price of $0.82 per share, held as a direct ownership position.
According to the footnote, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this transaction, the director beneficially holds 35,000 derivative securities related to Skye Bioscience common stock.
Skye Bioscience director Karen L. Smith reported receiving a stock option award. On 02/06/2026 she was granted an option to buy 35,000 shares of common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over the one-year period beginning January 19, 2026, and all 35,000 derivative securities are held directly.
Skye Bioscience reported that its Chief Financial Officer, Kaitlyn Arsenault, received a grant of stock options on February 6, 2026. The award covers 125,000 options to buy common stock at an exercise price of $0.82 per share. The options vest in equal monthly installments over a four-year period beginning January 19, 2026, aligning her long-term compensation with the company’s share performance.
Skye Bioscience Chief Scientific Officer granted 150,000 stock options. Christopher Twitty received a stock option for 150,000 shares of common stock at an exercise price of $0.82 per share on February 6, 2026. All 150,000 options are held directly.
The option vests in equal monthly installments over a four-year period beginning January 19, 2026, meaning portions become exercisable each month over that timeframe rather than all at once.
Skye Bioscience director Deborah H. Charych received stock options for 35,000 shares of common stock. The options have an exercise price of $0.82 per share and were granted on February 6, 2026. They vest in equal monthly installments over a one-year period beginning January 19, 2026, and expire on February 6, 2036.
Skye Bioscience director Annalisa Jenkins received a grant of stock options covering 35,000 shares of common stock on February 6, 2026. The options have an exercise price of $0.82 per share and expire on February 6, 2036.
According to the filing, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this grant, Jenkins beneficially owns 35,000 stock options, held directly.
Skye Bioscience Chief Development Officer granted 125,000 options to buy common stock at an exercise price of $0.82 per share. The award was made on February 6, 2026 and expires on February 6, 2036.
The stock option vests in equal monthly installments over four years beginning January 19, 2026, meaning the officer earns the right to exercise more of the grant every month during that period, as long as service conditions are met.
Skye Bioscience Chief Medical Officer granted stock options. On February 6, 2026, Chief Medical Officer Puneet S. Arora received a stock option to buy 125,000 shares of Skye Bioscience common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over four years beginning January 19, 2026, and is held directly by the reporting person.
Skye Bioscience Chief Executive Officer and director Punit Dhillon reported a grant of stock options. On February 6, 2026, he was awarded an option to buy 280,000 shares of common stock at an exercise price of $0.82 per share, held directly.
The option vests in equal monthly installments over a four-year period beginning January 19, 2026 and expires on February 6, 2036. Following this grant, Dhillon beneficially owns 280,000 derivative securities in the form of this stock option.